Table 3.
Multivariate Cox regression model of the probability of virological failure of INI-containing regimens after switching from PI
| aHR | IC 95% | p value | |
|---|---|---|---|
| Age (x 1 yrs more) | 1.01 | 0.97–1.05 | 0.725 |
| Previous cART regimens (x 1 more) | 1.12 | 1.00–1.24 | 0.046 |
| Previous VF | 1.89 | 0.74–4,78 | 0.181 |
| Male vs Female | 2.84 | 0.98–8,17 | 0.053 |
| ATVub vs ATV | 0.63 | 0.18–2.24 | 0.473 |
| DRV vs ATV | 2.71 | 0.77–9.57 | 0.121 |
| LPV vs ATV | 1.17 | 0.39–3.52 | 0.783 |
| fAPV vs ATV | 1.12 | 0.32–3.96 | 0.859 |
| DTG vs RAL | 0.17 | 0.02–1.52 | 0.113 |
| EVG vs RAL | 0.92 | 0.28–3.06 | 0.898 |
| TDF/FTC vs ABC/3TC | 2.87 | 0.62–13.25 | 0.176 |
| Other vs ABC/3TC | 1.85 | 0.41–8.46 | 0.425 |
| HIV-RNA > 50 cp/mL | 2.80 | 1.22–6.45 | 0.015 |
| CD4 > 500 cells/mmc | 0.90 | 0.32–2.57 | 0.851 |
| CD4 nadir < 200 cells/mmc | 0.44 | 0.15–1.30 | 0.138 |
| HCV coinfection | 1.01 | 0.39–2.58 | 0.986 |
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; yrs, years; cART, combined antiretroviral therapy; cps, copies; ATV, boosted atazanavir; ATVub, unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted fosamprenavir; DTG, dolutegravir; RAL, raltegravir; EVG, elvitegravir; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine; ABC/3TC, abacavir/lamivudine.